Italia Markets closed

Emergent BioSolutions Inc. (0IGA.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
4,9800+0,4001 (+8,74%)
Alla chiusura: 05:36PM BST
Schermo intero
Chiusura precedente4,5799
Aperto4,8300
Denaro0,0000 x N/D
Domanda0,0000 x N/D
Min-Max giorno4,7907 - 5,0400
Intervallo di 52 settimane1,4800 - 13,4182
Volume15.455
Media Volume19.429
Capitalizzazione219,908M
Beta (mensile su 5 anni)1,24
Rapporto PE (ttm)1,68
EPS (ttm)2,9670
Prossima data utili06 ago 2024 - 12 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

    GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent’s 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. “Neal and Don bring unique and extensive expertise to Emergent as the company defines

  • GlobeNewswire

    Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency

    NARCAN® Nasal Spray Carton, Two Doses This media asset is free for editorial broadcast, print, online and radio use. It is restricted for use for other purposes. Emergent requests acknowledgement of these images with a "Courtesy of Emergent" statement below each image. NARCAN® Nasal Spray In Use This media asset is free for editorial broadcast, print, online and radio use. It is restricted for use for other purposes. Emergent requests acknowledgement of these images with a "Courtesy of Emergent"

  • GlobeNewswire

    Emergent BioSolutions Reports Financial Results for Second Quarter 2023

    Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56MUpdates FY 2023 guidance and provides initial Q3 2023 forecast for total revenues GAITHERSBURG, Md., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2023. It also announced strategic steps to reduce investment in and de-emphasize focus on growth in its CDMO business. “Emergent has achi